Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | Pevonedistat with azacitidine for high-risk MDS

Moshe Mittelman • 5 Mar 2020
MDS 2020
Myelodysplastic Syndromes Azacitidine Pevonedistat

Moshe Mittelman, MD, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel, discusses the use of pevonedistat as a combination therapy with azacitidine to treat high-risk myelodysplastic syndromes (MDS). This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from Moshe Mittelman

4:16
Pre-MDS states: identifying patients at risk and using modern tools to improve prognosis
Moshe Mittelman • 5 May 2023
3:39
The role of inflammation in MDS & the potential to target it to prevent and treat MDS
Moshe Mittelman • 5 May 2023
3:37
Lymphoid aggregates as a potential prognostic factor for MDS
Moshe Mittelman • 5 May 2023
1:41
Using cytogenetics to improve the diagnosis and prognosis of MDS & to predict response to treatment
Moshe Mittelman • 5 May 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
3:19
Key clinical trials in MDS taking place in the US
Guillermo Garcia-Manero • 9 Apr 2024
1:34
Sequencing of agents in LR-MDS
Guillermo Garcia-Manero • 9 Apr 2024
1:21
HMAs for MDS- a party of one
Guillermo Garcia-Manero • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals